Literature DB >> 2574053

Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

H Perrild1, L Kayser, H E Poulsen, L Skovsted, B Jørgensen, J M Hansen.   

Abstract

1. Antipyrine (1000 mg orally) clearance was studied 3 days before treatment with either atenolol (50 mg twice daily), metoprolol (100 mg twice daily), propranolol (80 mg twice daily) or placebo, and at day 5 and 18 during treatment. Phenytoin (100 mg intravenously) clearance was measured on days 0, 7 and 21 during treatment. 2. Antipyrine clearance was decreased by about 20% after 5 days of treatment with either propranolol or atenolol and this decrease persisted after 18 days of treatment. Antipyrine clearance did not change during treatment with either metoprolol or placebo. Phenytoin clearance did not change during any of the treatments.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574053      PMCID: PMC1380015          DOI: 10.1111/j.1365-2125.1989.tb03541.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

Review 1.  Antipyrine as a model drug to study hepatic drug-metabolizing capacity.

Authors:  H E Poulsen; S Loft
Journal:  J Hepatol       Date:  1988-06       Impact factor: 25.083

2.  Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism.

Authors:  J M Hansen; M Kristensen; L Skovsted
Journal:  Epilepsia       Date:  1968-03       Impact factor: 5.864

3.  Unaltered metabolism of phenytoin in thyroid disorders.

Authors:  J Mølholm Hansen; L Skovsted; J P Kampmann; B I Lumholtz; K Siersbaek-Nielsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-05

4.  Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.

Authors:  T P Sloan; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

5.  Optimal sampling times for minimum variance of clearance determination.

Authors:  M Døssing; A Vølund; H E Poulsen
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

6.  Lack of effect of atenolol on antipyrine clearance.

Authors:  G T Tucker; N D Bax; M S Lennard; K Crewe; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

7.  Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.

Authors:  N D Bax; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

8.  The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.

Authors:  T K Daneshmend; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man.

Authors:  N D Bax; R W Jones; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

10.  Impairment of antipyrine clearance in humans by propranolol.

Authors:  D J Greenblatt; K Franke; D H Huffman
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

View more
  2 in total

1.  Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.

Authors:  Gudrun Hefner; Stefan Unterecker; Mohamed E E Shams; Margarete Wolf; Tanja Falter; Ekkehard Haen; Christoph Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2015-05-05       Impact factor: 3.575

2.  The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.

Authors:  J Kallio; R Huupponen; M Seppälä; E Säkö; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.